The mTOR pathway in the antiphospholipid syndrome

Area of Science:

• Immunology
• Molecular Biology
• Pathology

Background:

• Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by recurrent thrombosis and pregnancy complications.
• The underlying mechanisms of APS involve complex interactions between immune cells and antiphospholipid antibodies (aPLs).

Purpose of the Study:

• To review and synthesize current evidence on the role of the mTOR pathway in the pathogenesis of APS.
• To explore the potential of mTOR inhibitors as a therapeutic strategy for APS.

Main Methods:

• Literature review of studies investigating mTOR signaling in APS.
• Analysis of data concerning endothelial cells, platelets, and monocytes in APS.
• Examination of the impact of antiphospholipid antibodies (aPLs) on mTOR signaling.

Main Results:

• The mTOR pathway is activated in various cell types relevant to APS pathogenesis, including endothelial cells, platelets, and monocytes.
• aPLs can modulate mTOR signaling, contributing to pro-thrombotic and pro-inflammatory responses.
• Evidence suggests that mTOR inhibition may counteract key pathogenic mechanisms in APS.

Conclusions:

• The mTOR pathway represents a significant contributor to APS pathophysiology.
• Targeting mTOR offers a promising therapeutic avenue for managing APS and preventing its complications.